secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K/A
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001104659-23-040901
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics amends charter to 425M shares; corrects shareholder vote totals
--------------------------------------------------------------------------------

- Charter amendment approved: 149,648,555 for, 6,186,516 against, 313,654 abstentions.
- Three Class I directors elected: Yezan Haddadin, Kurt J. Hilzinger, Faisal G. Sukhtian to serve until 2026.
- Stockholders approved potential issuance >19.99% of common upon conversion of convertible note at below Nasdaq minimum price.
- KPMG ratified as auditor for FY ending September 30, 2023; advisory vote on executive compensation passed.
- Filing amends prior 8-K to correct previously reported voting results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923040901/0001104659-23-040901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923040901/tm2311203d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-040901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer